Long COVID News
The latest research, clinical trials, and breakthroughs — all in one place. No misinformation, no noise.
NIH RECOVER-TLC Trial Begins Testing LDN, Baricitinib, and Semaglutide for Long COVID
The largest Long COVID clinical trial platform is now testing three new treatments. Low-dose naltrexone (LDN), the JAK inhibitor baricitinib, and semaglutide (Ozempic) are being evaluated in thousands of patients. Results expected throughout 2026.
New Study Confirms Blood-Brain Barrier Disruption in Long COVID Brain Fog
Research published in Nature Neuroscience using advanced MRI confirms that the blood-brain barrier is damaged in Long COVID patients with cognitive symptoms. The frontal and temporal lobes — governing memory and executive function — are most affected.
Dutch RECLAIM Trial Launches: Testing Metformin and Colchicine
The Netherlands launches its first large-scale Long COVID treatment trial. Led by Stichting Long COVID and six university medical centers, RECLAIM is testing metformin and colchicine against standard care.
Post-Exertional Malaise: Two-Day CPET Studies Show Exercise Worsens Aerobic Capacity
New cardiopulmonary exercise testing data confirms that Long COVID patients with PEM show reduced aerobic capacity on day 2 of testing — the opposite of healthy individuals. This provides objective evidence against graded exercise therapy.
RECOVER-SLEEP Trial Testing Modafinil and Melatonin for Long COVID Sleep Dysfunction
The NIH is actively testing modafinil for hypersomnia and melatonin combined with light therapy for insomnia in Long COVID patients. Sleep disturbances affect 40-75% of patients.
Gut Microbiome Disruption Linked to Long COVID Symptom Severity
A comprehensive study confirms that SARS-CoV-2 profoundly disrupts the gut microbiome, and the degree of disruption correlates with Long COVID symptom severity. Dietary interventions targeting gut health may help.
400 Million People Worldwide Now Living with Long COVID
Updated global estimates suggest over 400 million people are currently experiencing Long COVID symptoms. The WHO calls for urgent scaling of research funding and clinical care infrastructure.
Low-Dose Naltrexone Shows Promise: 62% Report Improved Energy
An observational study of Long COVID patients on LDN (1-5mg/day) found 62% reported improved energy and 45% reported reduced brain fog. Formal RCTs are now underway in the NIH RECOVER platform.
All articles are curated from peer-reviewed journals and trusted sources. Summaries are for informational purposes only.